首頁 > 市場調查報告書 > 製藥

精神疾病

市場調查報告書

商品編碼

2103092

全球憂鬱症病例分析與預測：2026-2035年

Global Depression Patient Population Analysis and Forecast, 2026 - 2035

出版日期: 2026年07月17日 | 出版商:

Knowledge Sourcing Intelligence | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

對全球憂鬱症人數的分析表明，在預測期（2026-2035 年）內，預計會出現較高的複合年成長率 (CAGR)。

已開發國家和新興國家精神疾病負擔日益加重，全球憂鬱症患者人數持續成長。憂鬱症仍然是全球最常見的精神疾病之一，也是導致殘疾、生產力下降和生活品質降低的主要原因。患者群體分析市場提供關於疾病盛行率、發病率、確診和治療患者人數、人口趨勢、疾病嚴重程度、治療模式以及未來流行病學預測的全面洞察。這些分析有助於製藥公司、醫療保健提供者、研究機構、政策制定者和投資者規劃臨床開發、商業策略、醫療資源分配以及改善患者就醫途徑的舉措。

憂鬱症盛行率的上升是由多種人口統計、社會經濟和生活方式因素共同驅動的。人口成長、老化、都市化、經濟不確定性、慢性疾病、藥物濫用、社會孤立以及人們對心理健康意識的提高，都導致了憂鬱症診斷人數的增加。此外，篩檢計畫、基層醫療診斷和心理健康教育的改進，使得更多先前未被診斷的患者得以被發現，並擴大了可能接受治療的人群範圍。全球流行病學研究持續表明，女性患憂鬱症的機率顯著高於男性，而老年人和弱勢群體中的憂鬱症負擔正在急劇加重。

隨著製藥公司開發針對重度憂鬱症、難治性憂鬱症、產後憂鬱症、青少年憂鬱症和老年憂鬱症的標靶治療，患者人口統計分析變得日益重要。詳細的流行病學評估有助於機構識別服務不足的病患小組，評估商業性機會，最佳化臨床試驗招募，並預測未來的治療需求。隨著精準精神病學和基於生物標記的治療方法不斷發展，基於疾病亞型、嚴重程度、遺傳因素、共病和治療反應的患者細分正成為市場規劃不可或缺的一部分。

電子健康記錄、真實世界數據、人工智慧和先進醫學分析技術的日益普及，正在提高患者群體研究的準確性。這些技術使研究人員能夠利用大規模臨床資料集來評估疾病隨時間的進展、醫療服務利用、治療依從性以及區域差異。加之對精神健康基礎設施和全球精神衛生計劃的投入不斷增加，預計這些舉措將在整個預測期內持續推動憂鬱症患者群體分析的擴展。

市場促進因素

全球憂鬱症盛行率不斷上升

憂鬱症在全球範圍內持續影響越來越多的人，並且仍然是導致殘疾的主要原因之一。人口成長、預期壽命延長以及人們對精神疾病的認知提高，都促使憂鬱症確診人數持續增加。

醫療專業人員和公眾意識的提高，提高了診斷率，促進了早期療育。

改善心理健康篩檢

在醫療保健系統中，標準化心理健康篩檢計畫在基層醫療和專科醫療機構的應用日益廣泛。這些早期診斷措施有助於識別不同患者群體的憂鬱症，包括青少年、老年人和慢性病患者。

改進篩檢有助於更準確地進行流行病學評估，並擴大治療覆蓋範圍。

擴展真實世界數據分析

電子健康記錄、醫療保健資料庫、保險索賠數據、患者登記冊和數位健康平台提供了有價值的流行病學信息，可用於分析患者群體。

進階分析有助於更深入地了解疾病流行情況、治療模式、醫療保健服務利用和長期臨床結果。

加大對心理健康研究的投資

各國政府、醫療機構、製藥公司和學術機構持續增加對憂鬱症研究和流行病學研究的投入。

這些投資改善了疾病監測、病患登記和以人群為基礎的醫療保健規劃，同時也支持了創新療法的發展。

人們越來越關注精準精神病學

隨著精神病學向個人化發展，對患者進行詳細分層的需求日益成長。研究人員正在探索臨床特徵、生物標記、基因譜、疾病嚴重程度和治療反應模式，以改善個人化治療策略。

全面的患者群體分析為精準醫療和未來療法的研發提供了支持。

市場限制因素

憂鬱症診斷不足

社會歧視、醫療保健資源有限以及對心理健康缺乏認知，意味著相當一部分憂鬱症患者仍未被診斷出來。

未確診的患者會為流行病學估計帶來不確定性，並降低患者群體的預測準確性。

診斷標準的差異

各國在診斷實踐、篩檢調查方法、通報系統和醫療保健服務取得方面的差異可能會影響盛行率估計。

這些差異可能會使不同地區之間的流行病學數據直接比較變得困難。

缺乏心理健康基礎設施

許多中低收入國家仍面臨精神衛生專業人員、精神科設施和診斷資源短缺的問題。

由於醫療基礎設施有限，患者身分識別可能不完整，這可能導致對實際疾病負擔的低估。

The global depression patient population continues to expand, reflecting the growing burden of mental health disorders across developed and emerging economies. Depression remains one of the most prevalent psychiatric conditions worldwide and is a leading cause of disability, reduced productivity, and diminished quality of life. The patient population analysis market provides comprehensive insights into disease prevalence, incidence, diagnosed and treated populations, demographic trends, disease severity, treatment patterns, and future epidemiological projections. These analyses support pharmaceutical companies, healthcare providers, research organizations, policymakers, and investors in planning clinical development, commercial strategies, healthcare resource allocation, and patient access initiatives.

The increasing prevalence of depression is being driven by multiple demographic, socioeconomic, and lifestyle factors. Population growth, aging populations, urbanization, economic uncertainty, chronic illnesses, substance abuse, social isolation, and heightened awareness of mental health are contributing to a larger diagnosed patient pool. Improvements in screening programs, primary care diagnosis, and mental health education have also increased the identification of previously undiagnosed patients, expanding the addressable treatment population. Global epidemiological studies continue to demonstrate that women experience depression at significantly higher rates than men, while disease burden increases substantially among older adults and vulnerable populations.

Patient population analysis has become increasingly important as pharmaceutical companies develop targeted therapies for major depressive disorder, treatment-resistant depression, postpartum depression, adolescent depression, and geriatric depression. Detailed epidemiological assessments help organizations identify underserved patient groups, estimate commercial opportunities, optimize clinical trial recruitment, and forecast future treatment demand. As precision psychiatry and biomarker-guided treatment approaches continue to evolve, patient segmentation based on disease subtype, severity, genetics, comorbidities, and treatment response is becoming an essential component of market planning.

The growing adoption of electronic health records, real-world evidence, artificial intelligence, and advanced healthcare analytics is improving the accuracy of patient population studies. These technologies enable researchers to evaluate longitudinal disease progression, healthcare utilization, treatment adherence, and regional disease variations using large-scale clinical datasets. Combined with increasing investment in mental healthcare infrastructure and global mental health initiatives, these developments are expected to support continued expansion of depression patient population analysis throughout the forecast period.

Market Drivers

Rising Global Prevalence of Depression

Depression continues to affect a growing number of individuals worldwide and remains one of the leading contributors to disability. Population growth, increasing life expectancy, and greater recognition of mental health disorders are contributing to continuous expansion of the diagnosed patient population.

Growing awareness among healthcare professionals and the general public is improving diagnosis rates and encouraging earlier intervention.

Improved Mental Health Screening

Healthcare systems are increasingly implementing standardized mental health screening programs within primary care and specialty settings. Early diagnosis initiatives enable identification of depression across diverse patient populations, including adolescents, older adults, and individuals with chronic medical conditions.

Improved screening contributes to more accurate epidemiological assessments and expanded treatment access.

Expansion of Real-World Data Analytics

Electronic medical records, healthcare databases, insurance claims, patient registries, and digital health platforms are providing valuable epidemiological information for patient population analysis.

Advanced analytics improve understanding of disease prevalence, treatment patterns, healthcare utilization, and long-term clinical outcomes.

Increasing Investment in Mental Health Research

Governments, healthcare organizations, pharmaceutical companies, and academic institutions continue expanding investments in depression research and epidemiological studies.

These investments improve disease surveillance, patient registries, and population-based healthcare planning while supporting development of innovative therapies.

Growing Focus on Precision Psychiatry

The transition toward personalized mental healthcare is increasing demand for detailed patient segmentation. Researchers are analyzing clinical characteristics, biomarkers, genetic profiles, disease severity, and treatment response patterns to improve individualized treatment strategies.

Comprehensive patient population analysis supports precision medicine initiatives and future therapeutic development.

Market Restraints

Underdiagnosis of Depression

A substantial proportion of individuals experiencing depression remain undiagnosed due to social stigma, limited healthcare access, and inadequate mental health awareness.

Undiagnosed patients create uncertainty in epidemiological estimates and may reduce the accuracy of patient population forecasting.

Variability in Diagnostic Criteria

Differences in diagnostic practices, screening methodologies, reporting systems, and healthcare accessibility across countries can influence prevalence estimates.

These variations may complicate direct comparison of epidemiological data between regions.

Limited Mental Health Infrastructure

Many low-income and middle-income countries continue to experience shortages of mental health professionals, psychiatric facilities, and diagnostic resources.

Limited healthcare infrastructure may result in incomplete patient identification and underestimation of the true disease burden.

Technology and Segment Insights

By Disease Type

Major depressive disorder represents the largest patient population segment due to its high global prevalence and significant impact on public health.

Treatment-resistant depression represents an increasingly important subgroup as clinicians seek alternative therapies for patients who do not achieve adequate responses to conventional antidepressants.

Additional patient population analyses include persistent depressive disorder, postpartum depression, bipolar depression, seasonal affective disorder, and adolescent depression.

By Patient Demographics

Adults account for the largest proportion of diagnosed depression patients globally. Working-age populations experience significant disease burden due to occupational stress, chronic illnesses, and socioeconomic pressures.

Older adults represent one of the fastest-growing patient segments as aging populations increase worldwide. Depression among elderly individuals is frequently associated with chronic diseases, cognitive decline, and social isolation.

Women continue to exhibit higher prevalence rates than men across most geographic regions, while adolescent and young adult populations are experiencing increasing diagnosis rates.

By Severity

Patients with mild and moderate depression comprise a substantial proportion of the diagnosed population and are commonly managed through pharmacological treatment, psychotherapy, or combined therapeutic approaches.

Severe depression, including treatment-resistant cases, accounts for a smaller but clinically significant segment requiring specialized psychiatric care, advanced pharmacotherapy, neuromodulation, or inpatient management.

By End User

Pharmaceutical companies represent the largest users of depression patient population analysis due to their need for epidemiological data supporting clinical development, commercial forecasting, and market access strategies.

Healthcare providers utilize patient population studies to optimize treatment planning and healthcare resource allocation.

Academic institutions, government agencies, research organizations, and healthcare consulting firms also rely extensively on epidemiological analyses to guide policy development and scientific research.

Regional Insights

North America represents the largest market for depression patient population analysis due to advanced healthcare infrastructure, comprehensive electronic health record systems, strong mental health awareness, and extensive epidemiological research capabilities. High diagnosis rates and broad access to psychiatric services contribute to detailed patient population assessments.

Europe maintains a significant position through well-established healthcare systems, national disease registries, and expanding mental health surveillance programs. Increasing investment in psychiatric research and personalized medicine supports continued market growth.

Asia Pacific is expected to experience the fastest growth during the forecast period. Rising mental health awareness, expanding healthcare infrastructure, increasing diagnosis rates, and growing adoption of digital healthcare technologies are strengthening epidemiological research across China, Japan, India, South Korea, and Australia.

Latin America and the Middle East & Africa are gradually improving mental healthcare access through healthcare modernization initiatives, expanded screening programs, and increased government investment in behavioral health services.

Competitive and Strategic Outlook

The global depression patient population analysis market is supported by epidemiology research organizations, healthcare analytics providers, pharmaceutical consulting firms, contract research organizations, and real-world evidence specialists. Competition is increasingly centered on delivering comprehensive epidemiological intelligence that supports strategic planning throughout the pharmaceutical development lifecycle.

Organizations are investing in artificial intelligence, predictive analytics, healthcare databases, electronic medical records integration, and real-world evidence platforms to improve the accuracy and depth of patient population analyses. Strategic collaborations between pharmaceutical companies, healthcare providers, academic institutions, and public health agencies continue to strengthen data availability and analytical capabilities.

Future market development is expected to focus on precision epidemiology, biomarker-based patient segmentation, longitudinal disease monitoring, and advanced forecasting models that support personalized medicine and targeted therapeutic development.

Conclusion

The global depression patient population analysis market is expected to expand steadily as the worldwide burden of depressive disorders continues to increase. Rising disease prevalence, improving diagnostic capabilities, growing mental health awareness, and expanding use of real-world healthcare data are expected to drive demand for comprehensive epidemiological intelligence. Although challenges related to underdiagnosis, regional variability, and healthcare access remain, advances in healthcare analytics, digital technologies, and precision psychiatry will continue to enhance patient population analysis and support strategic decision-making across the global depression treatment landscape.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Report Scope and Objectives
1.2 Key Findings
1.3 Global Patient Population Overview
1.4 Epidemiology Highlights
1.5 Disease Burden Assessment
1.6 Key Growth Trends
1.7 Strategic Insights
1.8 Future Outlook (2025-2045)

2. Disease Overview

2.1 Introduction to Depression
2.2 Disease Definition and Classification
- 2.2.1 Major Depressive Disorder (MDD)
- 2.2.2 Treatment-Resistant Depression (TRD)
- 2.2.3 Persistent Depressive Disorder (Dysthymia)
- 2.2.4 Postpartum Depression
- 2.2.5 Seasonal Affective Disorder
- 2.2.6 Adolescent Depression
- 2.2.7 Geriatric Depression
2.3 Disease Pathophysiology
2.4 Risk Factors and Comorbidities
2.5 Disease Burden and Socioeconomic Impact
2.6 Diagnostic Pathway Analysis
2.7 Challenges in Diagnosis and Treatment

3. Research Methodology and Epidemiology Assumptions

3.1 Study Methodology
3.2 Data Collection Framework
3.3 Epidemiology Modeling Approach
3.4 Patient Population Forecasting Methodology
3.5 Data Validation and Triangulation
3.6 Key Assumptions and Limitations

4. Global Depression Epidemiology Overview

4.1 Global Patient Population Overview
4.2 Global Prevalence Analysis (2025-2045)
4.3 Global Incidence Analysis (2025-2045)
4.4 Diagnosed Patient Population Analysis
4.5 Treated Patient Population Analysis
4.6 Disease Severity Assessment
4.7 Epidemiology Forecast Analysis

5. Patient Population Segmentation

5.1 By Disease Type
- 5.1.1 Major Depressive Disorder (MDD)
- 5.1.2 Treatment-Resistant Depression (TRD)
- 5.1.3 Persistent Depressive Disorder (Dysthymia)
- 5.1.4 Postpartum Depression
- 5.1.5 Seasonal Affective Disorder
- 5.1.6 Adolescent Depression
- 5.1.7 Geriatric Depression
5.2 By Disease Severity
- 5.2.1 Mild Depression
- 5.2.2 Moderate Depression
- 5.2.3 Severe Depression
5.3 By Gender
- 5.3.1 Male Population
- 5.3.2 Female Population
5.4 By Age Group
- 5.4.1 Pediatric Population (<18 Years)
- 5.4.2 Young Adults (18-24 Years)
- 5.4.3 Adults (25-44 Years)
- 5.4.4 Middle-Aged Population (45-64 Years)
- 5.4.5 Elderly Population (?65 Years)
5.5 By Treatment Status
- 5.5.1 Diagnosed Patients
- 5.5.2 Undiagnosed Patients
- 5.5.3 Treated Patients
- 5.5.4 Untreated Patients
5.6 By Care Setting
- 5.6.1 Primary Care Settings
- 5.6.2 Specialty Mental Health Centers
- 5.6.3 Hospital-Based Care
- 5.6.4 Community Mental Health Services

6. Epidemiological Trends and Disease Burden

6.1 Historical Epidemiology Trends
6.2 Disease Burden Analysis
6.3 Disability and Quality-of-Life Impact
6.4 Mortality and Suicide Risk Assessment
6.5 Comorbidity Analysis
6.6 Healthcare Resource Utilization
6.7 Future Epidemiological Trends

7. Diagnosed and Treated Population Analysis

7.1 Diagnosis Rate Assessment
7.2 Screening and Detection Trends
7.3 Treatment-Seeking Behavior Analysis
7.4 Treatment Coverage Assessment
7.5 Treatment Gap Analysis
7.6 Access to Mental Health Services
7.7 Future Diagnosis and Treatment Trends

8. Unmet Needs and Population Challenges

8.1 Diagnostic Challenges
8.2 Access-to-Care Barriers
8.3 Treatment Adherence Challenges
8.4 Regional Variability Assessment
8.5 Health Equity Considerations
8.6 Future Opportunities for Early Diagnosis

9. Geographical Analysis

9.1 North America
- 9.1.1 Total Prevalence
- 9.1.2 Total Incidence
- 9.1.3 Diagnosed Patient Population
- 9.1.4 Disease Type Distribution
- 9.1.5 Age-Specific Epidemiology
- 9.1.6 Gender-Specific Epidemiology
- 9.1.7 Forecast Analysis (2025-2045)
9.2 Europe
- 9.2.1 Total Prevalence
- 9.2.2 Total Incidence
- 9.2.3 Diagnosed Patient Population
- 9.2.4 Disease Type Distribution
- 9.2.5 Age-Specific Epidemiology
- 9.2.6 Gender-Specific Epidemiology
- 9.2.7 Forecast Analysis (2025-2045)
9.3 Asia-Pacific
- 9.3.1 Total Prevalence
- 9.3.2 Total Incidence
- 9.3.3 Diagnosed Patient Population
- 9.3.4 Disease Type Distribution
- 9.3.5 Age-Specific Epidemiology
- 9.3.6 Gender-Specific Epidemiology
- 9.3.7 Forecast Analysis (2025-2045)
9.4 Latin America
- 9.4.1 Total Prevalence
- 9.4.2 Total Incidence
- 9.4.3 Diagnosed Patient Population
- 9.4.4 Disease Type Distribution
- 9.4.5 Age-Specific Epidemiology
- 9.4.6 Gender-Specific Epidemiology
- 9.4.7 Forecast Analysis (2025-2045)
9.5 Middle East & Africa
- 9.5.1 Total Prevalence
- 9.5.2 Total Incidence
- 9.5.3 Diagnosed Patient Population
- 9.5.4 Disease Type Distribution
- 9.5.5 Age-Specific Epidemiology
- 9.5.6 Gender-Specific Epidemiology
- 9.5.7 Forecast Analysis (2025-2045)

10. Key Countries Analysis

10.1 United States
- 10.1.1 Total Prevalence
- 10.1.2 Total Incidence
- 10.1.3 Diagnosed Cases
- 10.1.4 Disease Type Distribution
- 10.1.5 Age-Specific Epidemiology
- 10.1.6 Gender-Specific Epidemiology
- 10.1.7 Forecast Analysis (2025-2045)
10.2 Canada
- 10.2.1 Total Prevalence
- 10.2.2 Total Incidence
- 10.2.3 Diagnosed Cases
- 10.2.4 Disease Type Distribution
- 10.2.5 Age-Specific Epidemiology
- 10.2.6 Gender-Specific Epidemiology
- 10.2.7 Forecast Analysis (2025-2045)
10.3 Germany
- 10.3.1 Total Prevalence
- 10.3.2 Total Incidence
- 10.3.3 Diagnosed Cases
- 10.3.4 Disease Type Distribution
- 10.3.5 Age-Specific Epidemiology
- 10.3.6 Gender-Specific Epidemiology
- 10.3.7 Forecast Analysis (2025-2045)
10.4 United Kingdom
- 10.4.1 Total Prevalence
- 10.4.2 Total Incidence
- 10.4.3 Diagnosed Cases
- 10.4.4 Disease Type Distribution
- 10.4.5 Age-Specific Epidemiology
- 10.4.6 Gender-Specific Epidemiology
- 10.4.7 Forecast Analysis (2025-2045)
10.5 France
- 10.5.1 Total Prevalence
- 10.5.2 Total Incidence
- 10.5.3 Diagnosed Cases
- 10.5.4 Disease Type Distribution
- 10.5.5 Age-Specific Epidemiology
- 10.5.6 Gender-Specific Epidemiology
- 10.5.7 Forecast Analysis (2025-2045)
10.6 Italy
- 10.6.1 Total Prevalence
- 10.6.2 Total Incidence
- 10.6.3 Diagnosed Cases
- 10.6.4 Disease Type Distribution
- 10.6.5 Age-Specific Epidemiology
- 10.6.6 Gender-Specific Epidemiology
- 10.6.7 Forecast Analysis (2025-2045)
10.7 Spain
- 10.7.1 Total Prevalence
- 10.7.2 Total Incidence
- 10.7.3 Diagnosed Cases
- 10.7.4 Disease Type Distribution
- 10.7.5 Age-Specific Epidemiology
- 10.7.6 Gender-Specific Epidemiology
- 10.7.7 Forecast Analysis (2025-2045)
10.8 China
- 10.8.1 Total Prevalence
- 10.8.2 Total Incidence
- 10.8.3 Diagnosed Cases
- 10.8.4 Disease Type Distribution
- 10.8.5 Age-Specific Epidemiology
- 10.8.6 Gender-Specific Epidemiology
- 10.8.7 Forecast Analysis (2025-2045)
10.9 Japan
- 10.9.1 Total Prevalence
- 10.9.2 Total Incidence
- 10.9.3 Diagnosed Cases
- 10.9.4 Disease Type Distribution
- 10.9.5 Age-Specific Epidemiology
- 10.9.6 Gender-Specific Epidemiology
- 10.9.7 Forecast Analysis (2025-2045)
10.10 India
- 10.10.1 Total Prevalence
- 10.10.2 Total Incidence
- 10.10.3 Diagnosed Cases
- 10.10.4 Disease Type Distribution
- 10.10.5 Age-Specific Epidemiology
- 10.10.6 Gender-Specific Epidemiology
- 10.10.7 Forecast Analysis (2025-2045)
10.11 South Korea
- 10.11.1 Total Prevalence
- 10.11.2 Total Incidence
- 10.11.3 Diagnosed Cases
- 10.11.4 Disease Type Distribution
- 10.11.5 Age-Specific Epidemiology
- 10.11.6 Gender-Specific Epidemiology
- 10.11.7 Forecast Analysis (2025-2045)
10.12 Australia
- 10.12.1 Total Prevalence
- 10.12.2 Total Incidence
- 10.12.3 Diagnosed Cases
- 10.12.4 Disease Type Distribution
- 10.12.5 Age-Specific Epidemiology
- 10.12.6 Gender-Specific Epidemiology
- 10.12.7 Forecast Analysis (2025-2045)

11. Competitive Landscape

11.1 Epidemiology Data Providers Overview
11.2 Mental Health Research Organizations
11.3 Disease Awareness Initiatives
11.4 Screening and Diagnostic Programs
11.5 Patient Registry Landscape
11.6 Population Health Management Trends

12. Company Profiles

12.1 Johnson & Johnson
- 12.1.1 Overview
- 12.1.2 Financials
- 12.1.3 Depression Portfolio Overview
- 12.1.4 Epidemiology-Based Commercial Strategy
- 12.1.5 Target Patient Population Focus
- 12.1.6 Market Expansion Strategy
- 12.1.7 Strategic Initiatives
- 12.1.8 Recent Developments
12.2 AbbVie Inc.
- 12.2.1 Overview
- 12.2.2 Financials
- 12.2.3 Depression Portfolio Overview
- 12.2.4 Epidemiology-Based Commercial Strategy
- 12.2.5 Target Patient Population Focus
- 12.2.6 Market Expansion Strategy
- 12.2.7 Strategic Initiatives
- 12.2.8 Recent Developments
12.3 Sage Therapeutics, Inc.
- 12.3.1 Overview
- 12.3.2 Financials
- 12.3.3 Depression Portfolio Overview
- 12.3.4 Epidemiology-Based Commercial Strategy
- 12.3.5 Target Patient Population Focus
- 12.3.6 Market Expansion Strategy
- 12.3.7 Strategic Initiatives
- 12.3.8 Recent Developments
12.4 Otsuka Pharmaceutical Co., Ltd.
- 12.4.1 Overview
- 12.4.2 Financials
- 12.4.3 Depression Portfolio Overview
- 12.4.4 Epidemiology-Based Commercial Strategy
- 12.4.5 Target Patient Population Focus
- 12.4.6 Market Expansion Strategy
- 12.4.7 Strategic Initiatives
- 12.4.8 Recent Developments
12.5 Lundbeck A/S
- 12.5.1 Overview
- 12.5.2 Financials
- 12.5.3 Depression Portfolio Overview
- 12.5.4 Epidemiology-Based Commercial Strategy
- 12.5.5 Target Patient Population Focus
- 12.5.6 Market Expansion Strategy
- 12.5.7 Strategic Initiatives
- 12.5.8 Recent Developments
12.6 Takeda Pharmaceutical Company Limited
- 12.6.1 Overview
- 12.6.2 Financials
- 12.6.3 Depression Portfolio Overview
- 12.6.4 Epidemiology-Based Commercial Strategy
- 12.6.5 Target Patient Population Focus
- 12.6.6 Market Expansion Strategy
- 12.6.7 Strategic Initiatives
- 12.6.8 Recent Developments
12.7 Neurocrine Biosciences, Inc.
- 12.7.1 Overview
- 12.7.2 Financials
- 12.7.3 Depression Portfolio Overview
- 12.7.4 Epidemiology-Based Commercial Strategy
- 12.7.5 Target Patient Population Focus
- 12.7.6 Market Expansion Strategy
- 12.7.7 Strategic Initiatives
- 12.7.8 Recent Developments
12.8 Biogen Inc.
- 12.8.1 Overview
- 12.8.2 Financials
- 12.8.3 Depression Portfolio Overview
- 12.8.4 Epidemiology-Based Commercial Strategy
- 12.8.5 Target Patient Population Focus
- 12.8.6 Market Expansion Strategy
- 12.8.7 Strategic Initiatives
- 12.8.8 Recent Developments
12.9 Compass Pathways plc
- 12.9.1 Overview
- 12.9.2 Financials
- 12.9.3 Depression Portfolio Overview
- 12.9.4 Epidemiology-Based Commercial Strategy
- 12.9.5 Target Patient Population Focus
- 12.9.6 Market Expansion Strategy
- 12.9.7 Strategic Initiatives
- 12.9.8 Recent Developments
12.10 Alto Neuroscience, Inc.
- 12.10.1 Overview
- 12.10.2 Financials
- 12.10.3 Depression Portfolio Overview
- 12.10.4 Epidemiology-Based Commercial Strategy
- 12.10.5 Target Patient Population Focus
- 12.10.6 Market Expansion Strategy
- 12.10.7 Strategic Initiatives
- 12.10.8 Recent Developments